Research and development of Zika virus vaccines.

Autor:	Dawes BE; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA., Smalley CA; Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA., Tiner BL; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA., Beasley DW; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.; Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX, USA.; World Health Organization Collaborating Center for Vaccine Research, Evaluation and Training on Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA.; Institutional Office of Regulated Nonclinical Studies, University of Texas Medical Branch, Galveston, TX, USA., Milligan GN; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.; Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX, USA.; World Health Organization Collaborating Center for Vaccine Research, Evaluation and Training on Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA.; Department of Pediatrics, University of Texas Medical Branch, Galveston, TX, USA., Reece LM; Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX, USA.; World Health Organization Collaborating Center for Vaccine Research, Evaluation and Training on Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA., Hombach J; Initiative for Vaccine Research, Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland., Barrett AD; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.; Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.; Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX, USA.; World Health Organization Collaborating Center for Vaccine Research, Evaluation and Training on Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA.
Jazyk:	angličtina
Zdroj:	NPJ vaccines [NPJ Vaccines] 2016 Jul 28; Vol. 1, pp. 16007. Date of Electronic Publication: 2016 Jul 28 (Print Publication: 2016).
DOI:	10.1038/npjvaccines.2016.7
Abstrakt:	Zika virus (ZIKV) is a member of the family Flaviviridae, genus Flavivirus, and is transmitted by Aedes sp. mosquitoes. There are three genetic lineages of ZIKV: the East African, West African and Asian lineages. Until recently, Zika fever (ZF) has normally been considered a rare, mild febrile disease, but reports since 2012 have shown potentially severe complications associated with ZIKV infection, including microcephaly and Guillain-Barré syndrome. There are no licensed vaccines for ZIKV; however, many vaccine platforms/approaches that have been utilised for other flavivirus vaccines are being applied to ZIKV. Given the current outbreak of ZIKV in the Americas with its associated risks to pregnancy, we summarise what is known about the virus, how knowledge of currently licensed flavivirus vaccines can be applied to ZIKV vaccine development and the assessments of potential challenges for ZIKV vaccine testing and evaluation. Competing Interests: The authors declare no conflict of interest.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu